<div id="readability-page-1"><p><span>Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report)</span> had its target price boosted by stock analysts at Wells Fargo &amp; Company  from $30.00 to $35.00 in a research report issued on Thursday,Benzinga reports. The brokerage presently has an &#34;overweight&#34; rating on the stock. Wells Fargo &amp; Company's price target would indicate a potential upside of 31.89% from the stock's current price.</p><ul><li>Wake Up to This Biotech Stock That Still Has Big Potential Upside</li></ul><p>Several other equities analysts have also commented on CNTA. Lifesci Capital upgraded shares of Centessa Pharmaceuticals to a &#34;strong-buy&#34; rating in a research report on Wednesday, September 3rd. Truist Financial  set a $30.00 target price on shares of Centessa Pharmaceuticals in a research report on Wednesday, November 5th. Guggenheim  reaffirmed a &#34;buy&#34; rating and set a $28.00 price target on shares of Centessa Pharmaceuticals in a report on Monday, October 6th. Stephens assumed coverage on Centessa Pharmaceuticals in a research report on Tuesday, October 28th. They set an &#34;overweight&#34; rating and a $35.00 price objective for the company. Finally, Oppenheimer started coverage on Centessa Pharmaceuticals in a research report on Friday, August 29th. They issued an &#34;outperform&#34; rating and a $40.00 target price on the stock. One equities research analyst  has rated the stock with a Strong Buy rating, ten have given a Buy rating and one  has given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $33.11.</p><p><b>Get Our Latest Stock Analysis on Centessa Pharmaceuticals</b></p><h2>Centessa Pharmaceuticals Stock Down 0.6%</h2><p>Shares of CNTA traded down $0.16 during midday trading on Thursday, hitting $26.54. The company had a trading volume of 829,726 shares, compared to its average volume of 1,090,736. The stock has a market cap of $3.55 billion, a price-to-earnings ratio of -14.56 and a beta of 1.56. The company's 50 day moving average price is $22.73 and its 200 day moving average price is $17.35. The company has a quick ratio of 10.57, a current ratio of 10.56 and a debt-to-equity ratio of 0.36. Centessa Pharmaceuticals has a 52 week low of $9.60 and a 52 week high of $27.18. </p><p>Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($0.41) earnings per share for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.02).  On average, equities research analysts predict that  Centessa Pharmaceuticals will post -1.6 EPS for the current year. </p><h2>Insider Buying and Selling at Centessa Pharmaceuticals</h2><p>In other news, insider Mario Alberto Accardi sold 8,172 shares of the business's stock in a transaction on Tuesday, September 16th. The stock was sold at an average price of $21.40, for a total transaction of $174,880.80. Following the sale, the insider directly owned 197,394 shares of the company's stock, valued at $4,224,231.60. The trade was a 3.98% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available at this link. Also, CTO Tia L. Bush sold 35,000 shares of the stock in a transaction on Wednesday, September 24th. The shares were sold at an average price of $24.00, for a total value of $840,000.00. Following the completion of the transaction, the chief technology officer owned 121,503 shares of the company's stock, valued at $2,916,072. This trade represents a 22.36% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 145,964 shares of company stock valued at $3,169,861. Corporate insiders own  7.09% of the company's stock. </p><h2>Institutional Inflows and Outflows</h2><p>Several hedge funds and other institutional investors have recently made changes to their positions in the company. Bank of New York Mellon Corp acquired a new stake in shares of  Centessa Pharmaceuticals during the first quarter valued at approximately $147,000.  Cerity Partners LLC purchased a new stake in shares of  Centessa Pharmaceuticals in the first quarter valued at $471,000.  Wildcat Capital Management LLC purchased a new stake in shares of  Centessa Pharmaceuticals in the first quarter valued at $4,053,000.  Windmill Hill Asset Management Ltd acquired a new stake in shares of  Centessa Pharmaceuticals in the first quarter worth $1,696,000.  Finally, XTX Topco Ltd grew its holdings in shares of  Centessa Pharmaceuticals by 81.0% during the first quarter. XTX Topco Ltd now owns 41,057 shares of the company's stock valued at $590,000 after buying an additional 18,377 shares in the last quarter. 82.01% of the stock is currently owned by institutional investors and hedge funds. </p><h2>Centessa Pharmaceuticals Company Profile</h2> (Get Free Report)<p>Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Centessa Pharmaceuticals</li><li>Stock Analyst Ratings and Canadian Analyst Ratings</li><li>AMD to $300 Looks Easy—Here’s Why $500 Could Be Next</li><li>The 3 Best Blue-Chip Stocks to Buy Now</li><li>$5B+ in Buybacks: What DraftKings, AppLovin, and Altria Are Telling You </li><li>Mastering Discipline: Overcoming Emotional Challenges In Trading</li><li>4 High-Yield Real Estate Stocks to Buy as Investors Get Defensive</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q05UQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q05UQQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Centessa Pharmaceuticals Right Now?</h2><p>Before you consider Centessa Pharmaceuticals, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Centessa Pharmaceuticals wasn't on the list.</p><p>While Centessa Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

CNTA

<p>Wells Fargo & Company raised their price target on Centessa Pharmaceuticals (NASDAQ:CNTA) from $30.00 to $35.00, giving the stock an "overweight" rating. This suggests a potential upside of 31.89% from its current price. Other analysts also have positive ratings on CNTA, with a consensus rating of "Moderate Buy" and an average target price of $33.11. Centessa Pharmaceuticals' stock is currently trading at $26.54, with a market cap of $3.55 billion.</p>

Centessa Pharmaceuticals (NASDAQ:CNTA) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says